Status:

UNKNOWN

Paclitaxel and Carboplatin Followed by Cisplatin and Radiation Therapy in Treating Patients With Stage IB, Stage II, Stage III, or Stage IVA Cervical Cancer

Lead Sponsor:

University College London Hospitals

Conditions:

Cervical Cancer

Eligibility:

FEMALE

18+ years

Phase:

PHASE2

Brief Summary

RATIONALE: Drugs used in chemotherapy, such as paclitaxel, carboplatin, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from di...

Detailed Description

OBJECTIVES: Primary * Determine the response rate, in terms of clinical or radiologic response at 12 weeks after completion of study therapy, in patients with stage IB2-IVA cervical cancer treated w...

Eligibility Criteria

Inclusion

  • DISEASE CHARACTERISTICS:
  • Histologically confirmed carcinoma of the cervix, including any of the following subtypes:
  • Squamous cell carcinoma
  • Adenocarcinoma
  • Adenosquamous cell carcinoma
  • Locally advanced disease (i.e., FIGO stage IB2-IVA disease)
  • Stage confirmed by examination under anesthesia, cystoscopy, and sigmoidoscopy with biopsy of any suspicious lesions in the bladder, vagina, or rectum
  • Disease suitable for treatment with radical intent using chemoradiotherapy
  • PATIENT CHARACTERISTICS:
  • ECOG performance status 0-1
  • Platelet count \> 100,000/mm\^3
  • Hemoglobin \> 12.5 g/dL
  • WBC \> 3,000/mm\^3
  • Absolute neutrophil count \> 1,500/mm\^3
  • Bilirubin \< 1.25 times upper limit of normal (ULN)
  • Glomerular filtration rate (GFR) normal by ethylenediaminetetraacetic acid (EDTA) OR creatinine clearance ≥ 60 mL/min
  • Placement of ureteric stents required for all patients with hydronephrosis, regardless of renal function
  • ALT or AST \< 2.5 times ULN
  • Not pregnant or nursing
  • Negative pregnancy test
  • No prior diagnosis of cancer, except basal cell skin cancer
  • No active cardiac disease
  • Deemed fit to receive chemoradiotherapy
  • ECG normal
  • PRIOR CONCURRENT THERAPY:
  • Not specified

Exclusion

    Key Trial Info

    Start Date :

    June 1 2005

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ESTIMATED

    End Date :

    Estimated Enrollment :

    50 Patients enrolled

    Trial Details

    Trial ID

    NCT00462397

    Start Date

    June 1 2005

    Last Update

    August 26 2013

    Active Locations (3)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (3 locations)

    1

    Leicester Royal Infirmary

    Leicester, England, United Kingdom, LE1 5WW

    2

    Royal Marsden - London

    London, England, United Kingdom, SW3 6JJ

    3

    University College of London Hospitals

    London, England, United Kingdom, WIT 3AA